Alzamend Neuro, Inc. (ALZN): R&D Expense
$3.63M
Year ended 2026-04-30
$2.97M
Trailing 12 months to 2026-07-31
-21.3%
3-year compound annual growth
+22.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-04-30 | $3.63M | +156.5% | 2026-07-22, From 2025-05-01 |
| 2025-04-30 | $1.41M | -78.1% | 2026-07-22, From 2024-05-01 |
| 2024-04-30 | $6.46M | -13.3% | 2025-07-22, From 2023-05-01 |
| 2023-04-30 | $7.45M | +43.2% | 2024-07-30, From 2022-05-01 |
| 2022-04-30 | $5.20M | +296.8% | 2023-07-27, From 2021-05-01 |
| 2021-04-30 | $1.31M | +22.6% | 2022-07-19, From 2020-05-01 |
| 2020-04-30 | $1.07M | n/a | 2021-07-29, From 2019-05-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | 2026-04-30 | $3.63M | +156.5% |
| Inhibitor Therapeutics, Inc. (INTI) | 2025-12-31 | $1.70M | -3.5% |
| Accustem Sciences Inc. (ACUT) | 2025-12-31 | $281.0K | +103.2% |
| Artelo Biosciences, Inc. (ARTL) | 2025-12-31 | $5.42M | -9.5% |
| BullFrog AI Holdings, Inc. (BFRG) | 2025-12-31 | $1.80M | -19.0% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $3.64M | +19.5% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.04M | -84.4% |
| Alaunos Therapeutics, Inc. (TCRT) | 2025-12-31 | $1.36M | +276.5% |
| InMed Pharmaceuticals Inc. (INM) | 2026-06-30 | $3.03M | +7.3% |
Compare ALZN, INTI, ACUT, ARTL side by side · Screen every company in Pharmaceutical Preparations ↗